Early observations and pilot data that first suggested a new direction
For the first decade of MS disease-modifying therapy (1993-2004), the escalation approach dominated: start with injectable interferons or glatiramer acetate, then escalate to more potent agents only after breakthrough disease. This conservative strategy reflected safety concerns about stronger immunosuppressants and limited understanding of MS natural history.
Proof
Landmark RCTs and pivotal trials that established the evidence base
AFFIRM (2006) demonstrated natalizumab reduced the annualised relapse rate by 68% versus placebo, the most potent effect seen to that point. The OPERA I and II trials (2017) established ocrelizumab (anti-CD20 B-cell depleting therapy) as superior to interferon beta-1a, with 46% lower relapse rates. ORATORIO simultaneously proved ocrelizumab effective in primary progressive MS — the first therapy to slow disability in this subtype. These results challenged the escalation paradigm by showing dramatically superior outcomes with potent agents.
Follow-up studies, subgroup analyses, and real-world validation
The early high-efficacy therapy (EHT) debate intensified as observational data suggested that starting with potent agents from diagnosis led to better long-term disability outcomes than escalation. Prospective trials including TREAT-MS and DELIVER-MS were designed to directly compare early high-efficacy versus escalation strategies. B-cell depleting therapies (ocrelizumab, ofatumumab) and cladribine expanded the toolkit of high-efficacy options.
Guidelines
Integration into clinical practice guidelines and recommendations
The AAN 2018 practice guidelines and subsequent EAN/ECTRIMS 2024 guidelines recognised the importance of discussing high-efficacy therapy from diagnosis, particularly for patients with poor prognostic factors. While not mandating a specific strategy, guidelines shifted from reflexive escalation to shared decision-making about early potent treatment.
AAN 2018 MS Guidelines
Discuss high-efficacy therapy from diagnosis; shared decision-making on escalation vs early intensive
Now
Current standard of care and ongoing research directions
The MS treatment landscape has over 20 approved disease-modifying therapies. The escalation-versus-early-high-efficacy debate continues, with prospective trials (TREAT-MS, DELIVER-MS) expected to provide definitive evidence. B-cell depleting therapies (ocrelizumab, ofatumumab) have become among the most prescribed agents. BTK inhibitors represent the next frontier, potentially addressing progressive disease mechanisms.
Should MS patients start with strong or mild treatment?+
This is the central debate in MS therapeutics. Traditional escalation starts mild and intensifies after breakthrough. Growing evidence suggests early high-efficacy therapy (e.g., ocrelizumab, natalizumab) produces better long-term disability outcomes, especially in patients with poor prognostic factors. Prospective trials (TREAT-MS, DELIVER-MS) aim to settle this question.
What are the most effective MS drugs available today?+
B-cell depleting therapies (ocrelizumab, ofatumumab) and natalizumab are among the most effective disease-modifying therapies. OPERA I/II showed ocrelizumab reduced relapse rates by 46% compared to interferon beta-1a. ORATORIO proved ocrelizumab was the first drug effective in primary progressive MS. Over 20 DMTs are now approved with varying efficacy-safety profiles.
